Spying synthetic lethal promise, Pfizer bets $25M on Zentalis, will support cancer trials UPDATE: Amgen opts to DARP-out after seeing early data from $550M Molecular Partners biobucks collab Zolgensma for dementia? AviadoBio gains orphan tag for one-dose gene therapy Sponsored: Using Knowledge Graphs to Drive Drug Discovery After phase 2 flop, BerGenBio posts new data on COVID-19 prospect Future shaky at Solid Bio as it shaves off 35% of workforce, chief operating officer plans exit BridgeBio strategy head departs amid company’s second round of layoffs this year 2 become 1: Caladrius and Cend merge into tumor-focused Lisata Therapeutics Cytovia inks SPAC merger to get natural killer cells prospects into the clinic Novartis spotlights BeiGene-partnered cancer immunotherapy data to move it earlier in the treatment paradigm Symeres buys Organix to enter lipids market and grow in the US Here's what CEOs at the US' top for-profit health systems earned in 2021 Intel lends its deep learning AI to DiA Imaging’s heart ultrasound analysis tech Sygnature Discovery buys Peak Proteins to bolster drug discovery business Centene's Michael Neidorff was the highest-paid payer CEO last year. Take a look at what other execs earned Featured Story | By Nick Paul Taylor Pfizer is throwing its weight behind Zentalis Pharmaceuticals’ synthetic lethality candidate, making a $25 million investment in its new partner and agreeing to jointly advance the prospect through the clinic. read more |
| |
|---|
|
| | Harness the power of eCOA in your next trial Keep patients at the center of care while increasing efficiencies, data integrity and regulatory compliance. IQVIA’s leaders will help you deploy strategic eCOA tools, maximize patient needs and acquire real-time insights that demonstrate results. Learn more. |
Top Stories By Annalee Armstrong After a peak at the earliest data for Molecular Partners’ DARPin therapy, Amgen is saying thanks but no thanks on the $550 million partnership. The company's Novartis-partnered COVID-19 therapy is also delayed. read more By James Waldron Move over, Zolgensma. A new one-dose therapy that could provide a similar mode of treatment for the red-hot therapy area of neurodegenerative disorders has received orphan designation from regulators on both sides of the Atlantic. read more Sponsored By: QIAGEN Digital Insights Biomedical knowledge graphs can power many different application in drug discovery. Learn which key feature you should look for and why. read more By Nick Paul Taylor The effort to establish bemcentinib as a COVID-19 drug continues. Eleven months after failing a phase 2 trial, the Danish biotech has shared data from a second, smaller trial that linked the drug to significant changes. read more By Gabrielle Masson Things are anything but stable at Solid Biosciences, a life sciences company targeting therapies for Duchenne muscular dystrophy, as it plans to cut over a third of its workforce—for the second time in two years—and Chief Operating Officer Joel Schneider, Ph.D., departs. read more By Max Bayer BridgeBio is cutting staff for the second time this year as the company continues to reel from a phase 3 defeat in December. At the same time, the company's chief strategy officer is headed for the exit. read more By James Waldron Not an acquisition but a “merger of equals.” That’s how Caladrius Biosciences and Cend Therapeutics have described their transformation into the newly christened Lisata Therapeutics. read more By Nick Paul Taylor Cytovia Therapeutics has found an $ISLE to dock at in the choppy waters of biotech public markets. The natural killer (NK) cell startup is set to merge with a SPAC to secure the cash to enter the clinic and try to get through to a data drop in 2024. read more By Kevin Dunleavy Less than two weeks after BeiGene won approval in China for tislelizumab in esophageal cancer, its Western partner, Novartis, is announcing data that it hopes will lead to endorsements for the PD-1 checkpoint inhibitor in the U.S. and Europe. read more By Gareth Macdonald European drug discovery services firm Symeres has acquired U.S. lipid maker and organic chemistry contractor Organix. read more By Dave Muoio A fresh flock of health system CEOs took home millions in salary, stock awards and other remuneration during Year Two of the COVID-19 pandemic. read more By Andrea Park Artificial intelligence developer DiA Imaging Analysis has a fever, and the only prescription is more AI. read more By Gareth Macdonald Preclinical contractor Sygnature Discovery has bought Peak Proteins, a chemistry services provider set up by ex-AstraZeneca protein biochemistry and structural biology scientists. read more By Paige Minemyer The CEOs at six major national insurers earned nearly $115 million combined in total compensation last year. read more Resources Sponsored By: H1 More than 570 clinical trials in Ukraine have been disrupted. Unanticipated disruptions to medical testing and clinical trials impede progress toward new breakthroughs and new therapies that millions of patients around the world hang their hope on. What role do rescue sites play? Sponsored by: United Cargo The United Cargo team has made a commitment to pharmaceutical and medical partners that we are equipped to support their vaccine transportation needs safely and effectively across our expansive global and domestic network. The safety and security of these commodities is our priority, and we are proud to be a trusted partner in these efforts. Download infographic now. Presented By: Springer Nature The journey of drug development in 2021 delivered to your inbox: top 10 AdisInsight drug profiles viewed, new drug profiles released, overview of drug launches, key deals, research trends in 2021 and much more (free of charge). Sponsored by: Blue Matter, strategic consultants in the life sciences What’s in store for the oncology market in 2022 and beyond? This paper looks at 5 trends driving the market. Sponsored by: Thermo Fisher Scientific Learn how to position quality as a central component within your raw material sourcing strategies for the chemicals used throughout your workflows. Download the free whitepaper from Thermo Fisher Scientific. Cancer Progress 2022: Hear from Leading Oncology Innovators May 10-12, 2022 | Virtual Fierce Trial Master File Summit May 2-4, 2022 | New Orleans, LA & Streaming Live Fierce Leaders in Life Sciences Forum May 24, 2022 | Free Virtual Event Fierce Digital Pharma Engage June 14-15, 2022 | Huntington Beach, CA Fierce Digital Pharma Innovation Week June 21-23, 2022 | Virtual Event Fierce Biotech Next Gen June 29-30, 2022 | Free Virtual Event Fierce Pharma PR & Communications Summit East July 19-20, 2022 | Jersey City, NJ Fierce New Product Planning Summit September 20-22, 2022 | Boston, MA Fierce Digital Pharma East October 18-20, 2022 | Philadelphia, PA & October 25-28, 2022 | Virtual Event Fierce Pharma Meeting Professionals Summit November 2-3, 2022 | Atlantic City, NJ Fierce European Trial Master File Summit November 14-16, 2022 | London, UK Fierce Launch Readiness for Medical Affairs & Communications Teams Summit November 30-December 1, 2022 | Virtual Event Fierce JPM Week 2023 January 2023 | San Francisco, CA & Virtual | 